All News

RheumNow Podcast square

Is Cannabis Safe? (6.7.2024)

Jack Cush, MD

Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!

Read Article
medical.marijuana

Cannabis Use is Common, But is it Safe?

Jack Cush, MD

Two current JAMA reports suggest that cannabis use is not only common, but that if heavily used may increase mortality rates.

Read Article
BP.jpg

Hypertension not associated with High NSAID Doses in AxSpA

Medscape

At the recent SPARTAN annual meeting in Cleveland, Dr. Jose Meade-Aguilar reported that amongst axial spondyloarthritis patients receiving nonsteroidal anti-inflammatory drugs, there was no difference in the risk for hypertension when comparing those on high vs. low dose NSAIDs.

Read Article
RheumNow Podcast square

The Window of Opportunity (5.24.2024)

Jack Cush, MD

Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?

Read Article
podcast logo

"Don't You Know Who I am?" (5.17.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?

Read Article
RheumNow Podcast square

Featured BSR Abstracts (5.2.2024)

Jack Cush, MD

Dr. Jack Cush muses on the news, journal reports, FDA announcements and the 2024 BSR abstracts just released.

Read Article
lung%2Cbright.jpg

Methotrexate Does Not Increase ILD Risk in Dermatomyositis

Jack Cush, MD

A cohort analysis of dermatomyositis (DM) patients starting immunomodulators finds that methotrexate use was not associated with an increased risk of interstitial lung disease (ILD).

Read Article
inflammati.png

Systemic Inflammation and Mortality in RA-ILD

Jack Cush, MD

Analysis of the German RABBIT registry shows that systemic inflammation, more so than disease activity, strongly influences all-cause mortality in patients with rheumatoid arthritis and prevalent interstitial lung disease (RA-ILD).

Read Article
RheumNow Podcast square

Rheum Chapter Notes (4.26.2024)

Jack Cush, MD

Dr. Jack Cush reviews this past week’s news and journal articles from RheumNow.com.

Read Article
RheumNow Podcast square

Canary in a Coal Mine (4.19.2024)

Jack Cush, MD

Dr. Jack Cush reviews regulatory reports, news and novel journal articles - this week focusing on Sjogren's, ILD, Gout and Uveitis.

Read Article
infx.pneumonia.jpg

RA-ILD at Higher Risk for Serious Infection and Death

Jack Cush, MD

A prospective, multicenter study from Spain has demonstrated higher rates of mortality and serious infection in rheumatoid arthritis–associated interstitial lung disease (RA-ILD) patients.

Read Article
Reminder of relevance of #Rheumatoid factor ⬆️RF also predicts cardiovascular events ⚠️ ⬆️disease activity ❗️Worse outcomes #EULAR2024 #RF #RA https://t.co/kXwh682ONp

Links:

Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
Nordic country analysis of mortality in RA (n 1145), RA-ILD (239), population ILD (378) & nl controls (1890) shows most mortality in pop ILD (HR 8.3), but less in RA-ILD (HR 3.6). Why is death less in latter; could it be RA therapies? Abstr #POS0022 # EULAR2025 https://t.co/wFZq49rIiW
Dr. John Cush RheumNow ( View Tweet)
OP0031 (2024) COMPARATIVE ANALYSIS OF TNF INHIBITORS AND IL17 INHIBITORS IN PSORIATIC ARTHRITIS: EXPLORING CARDIOVASCULAR OUTCOMES signif absolute risk difference 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

Danish Registry study of 1.9 million chronic pain pts, shows chronic use of medicinal cannabis (5391) is assoc w/ a significant risk of new-onset arrhythmia {180d RR 2.07; 1-year RR 1.36). No significant association for acute coronary syndrome https://t.co/VT3X8lVWaD https://t.co/BMqVapFkuU

Links:

Dr. John Cush RheumNow ( View Tweet)
Review article of Interstitial Lung Dz Assoc w/ Systemic Sclerosis. SSc-ILD prevalence ranges 25-95%; ILD is a main cause of morbidity and mortality, contributing to 35% of deaths https://t.co/8mMFbDu4gi https://t.co/nQ4GfNcMWt

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort study compared 5825 #AS pts vs 28,356 matched controls; showed an increased risk of pulmonary embolism w/ AS; not present pre-Dx ((0.4% vs 0.2%), but incr post-AS Dx (PE IR 11.6 vs 6.8/10KPY: adj HR 1.70;; p<0.001) https://t.co/wSkAMozvnL https://t.co/5Q470QkAxe

Links:

Dr. John Cush RheumNow ( View Tweet)
Systemic Inflammation and Mortality in RA-ILD Analysis of the German RABBIT registry shows that systemic inflammation, more so than disease activity, strongly influences all-cause mortality in patients with RA-ILD. https://t.co/Qjtg364Pv7 https://t.co/aTQxTcO6Yv

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA review of ILD; that affects 650,000 in USA, leading to 25,000-30,000 deaths/YR. Types reviewed. Key Symptoms: dyspnea and cough, w/ chest CT being diagnostic tool. Antifibrotic & immunomodulatory may slow disease progression. https://t.co/tE7kHgUE02 https://t.co/V7Htoct3VP

Links:

Dr. John Cush RheumNow ( View Tweet)
RA-ILD at Higher Risk for Serious Infection and Death A prospective, multicenter study from Spain has demonstrated higher rates of mortality and serious infection in rheumatoid arthritis–associated interstitial lung disease (RA-ILD) patients. https://t.co/cjmcNi0ZqL https://t.co/wUXNWNeyOa

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×